Abstract Background hMPV is a common cause of medically attended ARI (MA-ARI) in US children aged 5 years, but few data are available on disease burden in AI/AN children. For respiratory syncytial virus (RSV), another common cause of pediatric respiratory illness, hospitalization rates in AI/AN children 5 years historically have been higher than for the general US population 5 years (17-40/1000 in some remote AI/AN communities versus 4-6/1000). We describe the epidemiology of medically attended hMPV-associated ARI in AI/AN children and estimate incidence rates of hMPV-associated hospitalizations. Methods We conducted population-based surveillance for MA-ARI in hospitalized and outpatient AI/AN children aged 5 years in the Southwest US (Navajo Nation and White Mountain Apache Tribal lands) and Alaska (Yukon Kuskokwim Delta and Anchorage) during November 2019-May 2024. Nasal swabs were tested by PCR for hMPV and RSV. We described the seasonality of hMPV and RSV detection and compared the clinical presentation of children with hMPV-positive versus hMPV-negative MA-ARI using Fisher’s exact test and Wilcoxon rank sum test. We used Poisson regression to estimate annual hMPV-associated hospitalization incidence per 1000 children stratified by age and site. Results hMPV seasonality varied regionally but circulation typically followed the onset of the RSV season; the COVID-19 pandemic disrupted circulation during 2021 (Fig). Among the 2561 (90%) of 2836 enrollees with hMPV testing, hMPV was detected in 14% (1373/1591) of swabs from inpatient children and 8% (79/970) of swabs from outpatient children (Table 1). Clinical characteristics were generally similar in children with hMPV-positive compared to hMPV-negative MA-ARI. The incidence of HMPV-associated ARI hospitalization among children 5 years ranged from 0-16.0/1000 and age-group patterns varied by site and year (Table 2). Conclusion hMPV-associated hospitalization incidence rates in AI/AN children 5 years were lower than historical RSV-associated hospitalization rates in these same communities but similar to or greater than historical RSV rates in the general US child population. These findings provide a baseline for hMPV disease burden for assessments of future prevention products. Disclosures All Authors: No reported disclosures
Hartman et al. (Thu,) studied this question.